Ray Dalio's ABBV Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 260.7K shares of AbbVie Inc. (ABBV) worth $60.36 M, representing 0.24% of the portfolio. First purchased in 2020-Q4, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in ABBV, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 493.3K shares. Largest reduction occurred in Q3 2025, reducing 337.6K shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's AbbVie (ABBV) Holding Value Over Time
Track share changes against reported price movement
Quarterly AbbVie (ABBV) Trades by Ray Dalio
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2020 | +25,294 | New Buy | 25,294 | $107.14 |
| Q1 2021 | -25,294 | Sold Out | 25,294 | $0.00 |
| Q2 2021 | +52,605 | New Buy | 52,605 | $112.63 |
| Q3 2021 | +22,491 | Add 42.75% | 75,096 | $107.88 |
| Q4 2021 | -33,241 | Reduce 44.26% | 41,855 | $135.40 |
| Q1 2022 | +33,661 | Add 80.42% | 75,516 | $162.11 |
| Q2 2022 | +6,334 | Add 8.39% | 81,850 | $153.16 |
| Q3 2022 | +130,900 | Add 159.93% | 212,750 | $134.21 |
| Q4 2022 | -182,648 | Reduce 85.85% | 30,102 | $161.61 |
| Q1 2023 | +381,328 | Add 1266.79% | 411,430 | $159.37 |
| Q2 2023 | +222,875 | Add 54.17% | 634,305 | $134.73 |
| Q3 2023 | -58,345 | Reduce 9.20% | 575,960 | $149.06 |
| Q4 2023 | +30,933 | Add 5.37% | 606,893 | $154.97 |
| Q1 2024 | -157,114 | Reduce 25.89% | 449,779 | $182.10 |
| Q2 2024 | -161,254 | Reduce 35.85% | 288,525 | $171.52 |
| Q3 2024 | -83,953 | Reduce 29.10% | 204,572 | $197.48 |
| Q4 2024 | +81,791 | Add 39.98% | 286,363 | $177.70 |
| Q1 2025 | -181,411 | Reduce 63.35% | 104,952 | $209.52 |
| Q2 2025 | +493,340 | Add 470.06% | 598,292 | $185.62 |
| Q3 2025 | -337,603 | Reduce 56.43% | 260,689 | $231.54 |
Ray Dalio's AbbVie Investment FAQs
Ray Dalio first purchased AbbVie Inc. (ABBV) in Q4 2020, acquiring 25,294 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held AbbVie Inc. (ABBV) for 20 quarters since Q4 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's largest addition to AbbVie Inc. (ABBV) was in Q2 2025, adding 598,292 shares worth $111.05 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 260,689 shares of AbbVie Inc. (ABBV), valued at approximately $60.36 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, AbbVie Inc. (ABBV) represents approximately 0.24% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's peak holding in AbbVie Inc. (ABBV) was 634,305 shares, as reported at the end of Q2 2023. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.